What is Leerink Partnrs’ Estimate for TENX FY2026 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Stock analysts at Leerink Partnrs lowered their FY2026 EPS estimates for Tenax Therapeutics in a research report issued on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger now expects that the specialty pharmaceutical company will earn ($3.93) per share for the year, down from their previous estimate of ($3.91). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ FY2027 earnings at ($4.17) EPS and FY2028 earnings at ($2.70) EPS.

TENX has been the subject of several other research reports. Leerink Partners started coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price objective for the company. Guggenheim initiated coverage on Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price target for the company. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.00.

Tenax Therapeutics Price Performance

NASDAQ:TENX opened at $6.65 on Thursday. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $21.46. The firm has a 50 day moving average of $6.08 and a 200 day moving average of $4.72.

Hedge Funds Weigh In On Tenax Therapeutics

Hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. purchased a new position in Tenax Therapeutics during the 3rd quarter worth approximately $101,000. Stonepine Capital Management LLC acquired a new stake in shares of Tenax Therapeutics in the third quarter worth $173,000. Finally, Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics during the third quarter worth $288,000. 1.67% of the stock is owned by institutional investors and hedge funds.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.